ClinicalTrials.gg
RecruitingNCT06254391LowASA-PCIUpdated Feb 12, 2024

Aspirin Dose Comparison in Elderly PCI Patients: 30mg vs. 75mg in Acute Coronary Syndrome

A Phase 2 interventional study of Low-dose aspirin in Myocardial Infarction and Acute Coronary Syndrome, sponsored by Medical University of Warsaw. Recruiting at 1 site in Poland. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-12.

Sponsored by Medical University of Warsaw · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Jul 2023, registered Feb 2024).
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies testing aspirin in Myocardial Infarction — 7 open to participants now, 8 under way, 2 of them phase 3. Aspirin · Myocardial Infarction.

Planned enrollment
22nd of 28
40 · median 400
Started
2023
with 1 other
Phase 2
Only one
of the 29
Registered
25th of 29
by date

Among the 29 studies testing aspirin in Myocardial Infarction, this one is the 22nd largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2023, is the only one in phase 2, and was the 25th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

7 of the 29 studies testing aspirin in Myocardial Infarction are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing aspirin in Myocardial Infarction, or all of them as a file.
02

Study summary

Elderly patients undergoing percutaneous coronary intervention (PCI) face a high risk of both ischemic and hemorrhagic complications necessitating antiplatelet therapy. Previous data indicate that even at a dose of 20-30 mg/day, aspirin (ASA) allows almost complete inhibition of thromboxane (TX) A2 biosynthesis in healthy volunteers. However, ASA at a dose of 30 mg/day has not been evaluated in the acute phase of myocardial infarction or among elderly patients, where it may achieve an optimal balance between bleeding risk and ischemic complications.

This randomized study will include 40 patients over 65 years undergoing PCI for acute coronary syndrome (ACS). It compares a new dual antiplatelet therapy (DAPT) strategy consisting of a P2Y12 antagonist (ticagrelor) and ASA at a very low dose of 30 mg/day (n=20) against the current standard treatment (P2Y12 antagonist and ASA at a dose of 75 mg) (n=20) in the control group.

03

Conditions studied

  • Myocardial Infarction
  • Acute Coronary Syndrome

Keywords

  • Dual Antiplatelet Therapy
  • Myocardial Infarction
  • Acute Coronary Syndrome
  • Very-low dose aspirin
  • PCI
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age above 65 years
  • acute coronary syndrome (ACS)
  • positive results for myocardial necrosis markers (troponins)
  • undergoing successful coronary angioplasty with stent implantation within the last 24-48 hours before enrollment in the study
  • dual antiplatelet therapy (DAPT) containing ticagrelor

Exclusion criteria

Exclusion Criteria:

  • indications other than ACS and PCI for DAPT use
  • history of stent thrombosis during the course of DAPT
  • planned subsequent coronary artery revascularization
  • planned surgery requiring suspension or interruption of DAPT
  • planned discontinuation of ASA or P2Y12 antagonist during the study
  • use of doses other than 75 mg ASA once daily or non-use of a P2Y12 inhibitor - intake of diuretic drugs (e.g., loop diuretics, thiazides, potassium-sparing drugs)
  • intake or planned intake of oral anticoagulants, parenteral antithrombotic therapy (e.g., unfractionated heparin, low molecular weight heparin, bivalirudin), glycoprotein IIb/IIIa inhibitors (e.g., abciximab, tirofiban), fibrinolytic agents (e.g., tissue plasminogen activator), or nonsteroidal anti-inflammatory drugs
  • history of acute or chronic liver disease; severe kidney disease requiring dialysis; pregnancy; comorbidities associated with a predicted of less than 1 year
  • any other condition deemed by the investigator to impact hemostasis, coagulation, bleeding risk, or the ability to adhere to the study protocol; receiving a strong inhibitor of cytochrome P450 3A, simvastatin or lovastatin at doses greater than 40 mg per day, a narrow therapeutic index cytochrome P450 3A substrate (e.g., cyclosporine or quinidine), or a strong inducer of cytochrome P450 3A (e.g., rifampin, rifabutin, phenytoin, carbamazepine, phenobarbital)
  • hemodynamic instability; clinical condition preventing obtaining .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    Very low-dose aspirin first

    Patients will receive ASA 30mg per day (in the morning) for 14 days, followed by ASA 75mg per day (in the morning) for the next 14 days. All the participants will receive standard maintenance dose of ticagrelor 90mg twice a day as part of the DAPT therapy. All the participants will receive the loading dose of ASA 300mg before the PCI procedure.

    Drug: Low-dose aspirin

  • Other
    Standard low-dose aspirin first

    Patients will receive ASA 75mg per day (in the morning) for 14 days, followed by ASA 30mg per day (in the morning) for the next 14 days. All the participants will receive standard maintenance dose of ticagrelor 90mg twice a day as part of the DAPT therapy. All the participants will receive the loading dose of ASA 300mg before the PCI procedure.

    Drug: Low-dose aspirin

Interventions

06

What researchers measure

Primary outcomes

  1. Platelet reactivity (ASPI)

    Comparison of platelet reactivity dependent on arachidonic acid (ASPI test) in low-dose ASA therapy, assessed in impedance aggregometry in regards to group treated with DAPT with standard ASA 75mg dose after 14 days of therapy.

    Time frame: 14th day of treatment, 2h before ASA 30mg dose (through effect), and 2h after ASA 30mg dose (peak effect), in regards to group treated with DAPT with standard ASA 75mg dose after 14 days of therapy

Secondary outcomes

  1. Platelet reactivity (ADP)

    Comparison of platelet reactivity dependent on ADP (ADP test) in low-dose ASA therapy, assessed in impedance aggregometry in regards to the group treated with DAPT with standard ASA 75mg dose and level changes in individual patients.

    Time frame: Days 7, 14, and 28 of treatment, 2 hours before the administration of the next ASA dose (pre-dose - representing the trough effect), and 2 hours after the ASA dose (post-dose - representing the peak effect)

  2. Platelet reactivity (TRAP-6)

    Comparison of platelet reactivity dependent on TRAP-6 protein activating the thrombin receptor (TRAP test) in low-dose ASA therapy, assessed in impedance aggregometry in regards to group treated with DAPT with standard ASA 75mg dose and level changes in individual patients.

    Time frame: Days 7, 14, and 28 of treatment, 2 hours before the administration of the next ASA dose (pre-dose - representing the trough effect), and 2 hours after the ASA dose (post-dose - representing the peak effect)

  3. Platelet reactivity (ASPI)

    Comparison of platelet reactivity dependent on arachidonic acid (ASPI test) in low-dose ASA therapy, assessed in impedance aggregometry in regards to group treated with DAPT with standard ASA 75mg dose and level changes in individual patients.

    Time frame: Days 7, and 28 of treatment, 2 hours before the administration of the next ASA dose (pre-dose - representing the trough effect), and 2 hours after the ASA dose (post-dose - representing the peak effect)

  4. Bleeding time

    Comparison of bleeding time (assessed with lancet method) between two groups (ASA 30mg and ASA 75mg) and among the individual patients.

    Time frame: Days 7, 14, and 28 of treatment 2 hours after the administration of the ASA dose

  5. PGI2 levels

    Comparison of PGI2 concentration in urine between two groups (ASA 30mg and ASA 75mg) and among the individual patients.

    Time frame: Measured on days 7, 14, and 28 of treatment, 2 hours after the administration of the ASA dose

  6. TXB2 levels

    Comparison of TXB2 concentration between two groups (ASA 30mg and ASA 75mg) and among the individual patients.

    Time frame: Days 7, 14, and 28 of treatment, 2 hours before the administration of the next ASA dose, and 2 hours after the ASA dose

Other outcomes

  1. Safety monitoring

    Clinical endpoints (safety monitoring) will include an assessment of the composite endpoint comprising adverse cardiovascular events (MACE): death, myocardial infarction, stroke, and non-elective coronary artery revascularization within 3 months of PCI. The frequency of bleeding complications (BARC 1,2,3,4, or 5), and the frequency of confirmed and probable stent thrombosis defined by the Academic Research Consortium will also be evaluated.

    Time frame: 90th day

07

Study locations

1 of 1 sites recruiting
  • 1st Department and Clinic of Cardiology, Medical University of Warsaw
    Warsaw, Mazowieckie Voivodenship 02-097, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jul 2025, 24 months after the start.

Of 45 phase 2 interventional studies under Myocardial Infarction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 42. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2024
First posted
Feb 12, 2024
StartActual
Jul 3, 2023
Primary completionEst.
Jul 2025
CompletionEst.
Jul 2025
Last update
Feb 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06254391
Responsible party
Mariusz Tomaniak (Tomaniak Mariusz MD PhD Assoc. Prof., Medical University of Warsaw) — Principal investigator
First posted
Feb 12, 2024
Start date
Jul 3, 2023
Primary completion
Jul 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Feb 12, 2024

Study contacts

Mariusz Tomaniak, PhD
Contact
mariusz.tomaniak@wum.edu.pl
+48 22 599-19-58
Mariusz Tomaniak, PhD
principal investigator · 1st Department and Clinic of Cardiology, Medical University of Warsaw

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion